ovarian cancer

Enter your BioSpace account email address and password to log in now. Saint Vincent and the Grenadines Research Highlights Important Indicators of Early-stage Ovarian Cancer 11/12/2007 Uppsala. Sweden – November 09. 2007 – New research explains why some ovarian cancer patients are dying while others survive despite similar surgical and post-operative treatment. The findings show that the difference between life and death can many times be explained by the different biological properties of the tumors. Understanding ovarian cancer biomarkers such as clear cell tumors and the exploration of specific tumor-targeted therapy such as DNA profiling will improve early stage diagnosis. | | | | | | | | | © 2008 BioSpace. Inc an company Visit other onTargetjobs companies | | | | | | eLearners Online Degrees: | | |

Forex Groups - Tips on Trading

Related article:
http://www.biospace.com/news_story.aspx?StoryID=77041&full=1

comments | Add comment | Report as Spam

Kisspeptin and its receptor GPR54 guess a favourable clinical outcome in women with ovarian carcinoma and are specific for the clear cell carcinoma subtype research published this week in the online open access journal. BMC Medicine reveals. The kisspeptins a family of peptide hormones and the receptor GPR54 have previously been linked to anti-metastatic activity in certain human tumours. In this chew over scientists undergo shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian alter cell carcinoma - the first such markers to be identified. A research aggroup based at the BC Cancer Agency and Vancouver General Hospital. Vancouver. Canada created a tissue microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive the be contradict. The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as in comparison to those patients who were contradict for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Scientists also observed that these molecular markers were significantly linked to the clear cell ovarian carcinomas subtype. Few prognostic or predictive molecular markers for ovary cancer exist yet such markers could be vital for the early diagnosis and management of the disease. The authors declare that in the future serum kisspeptin levels could provide a means to monitor disease activity and kisspeptins may even have use as therapeutic agentsin women with ovarian alter cell carcinoma. These possibilities require further research however. They create verbally: "We evaluate that the strong association of GPR54 and kisspeptin expression with outcome and clear cell type in ovarian carcinoma will affect fresh approaches to what is still a lethally intractable disease."Posted by: Emily

Forex Groups - Tips on Trading

Related article:
http://medicineworld.org/cancer/lead/11-2007/predicting-the-future-in-ovarian-cancer.html

comments | Add comment | Report as Spam

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma and are specific for the clear cell carcinoma subtype research published this week in the online open access journal. BMC care for reveals. The kisspeptins a family of peptide hormones and the receptor GPR54 have previously been linked to anti-metastatic activity in certain human tumours. In this study scientists have shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian clear cell carcinoma - the first such markers to be identified. A research team based at the BC Cancer Agency and Vancouver command Hospital. Vancouver. Canada created a create from raw material microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive the rest contradict. The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as in comparison to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Scientists also observed that these molecular markers were significantly linked to the clear cell ovarian carcinomas subtype. Few prognostic or predictive molecular markers for ovary cancer exist yet such markers could be vital for the early diagnosis and management of the disease. The authors declare that in the future serum kisspeptin levels could provide a means to observe disease activity and kisspeptins may even have use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities demand further research however. They write: "We anticipate that the strong association of GPR54 and kisspeptin expression with outcome and clear cell type in ovarian carcinoma will affect fresh approaches to what is still a lethally intractable disease."Posted by: Emily

Forex Groups - Tips on Trading

Related article:
http://medicineworld.org/cancer/lead/11-2007/predicting-the-future-in-ovarian-cancer.html

comments | Add comment | Report as Spam

Kisspeptin and its receptor GPR54 guess a favourable clinical outcome in women with ovarian carcinoma and are specific for the clear cell carcinoma subtype research published this week in the online change state access journal. BMC Medicine reveals. The kisspeptins a family of peptide hormones and the receptor GPR54 have previously been linked to anti-metastatic activity in certain human tumours. In this study scientists undergo shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian clear cell carcinoma - the first such markers to be identified. A research team based at the BC Cancer Agency and Vancouver General Hospital. Vancouver. Canada created a tissue microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive the rest negative. The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as in comparison to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Scientists also observed that these molecular markers were significantly linked to the alter cell ovarian carcinomas subtype. Few prognostic or predictive molecular markers for ovary cancer exist yet such markers could be vital for the early diagnosis and management of the disease. The authors declare that in the future serum kisspeptin levels could give a means to monitor disease activity and kisspeptins may change surface have use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities require further research however. They write: "We anticipate that the strong association of GPR54 and kisspeptin expression with outcome and clear cell type in ovarian carcinoma will stimulate fresh approaches to what is still a lethally intractable disease."Posted by: Emily

Forex Groups - Tips on Trading

Related article:
http://medicineworld.org/cancer/lead/11-2007/predicting-the-future-in-ovarian-cancer.html

comments | Add comment | Report as Spam

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma and are specific for the alter cell carcinoma subtype research published this week in the online open access journal. BMC Medicine reveals. The kisspeptins a family of peptide hormones and the receptor GPR54 have previously been linked to anti-metastatic activity in certain human tumours. In this chew over scientists have shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian clear cell carcinoma - the first such markers to be identified. A investigate team based at the BC Cancer Agency and Vancouver command Hospital. Vancouver. Canada created a tissue microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive the rest negative. The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as in comparison to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Scientists also observed that these molecular markers were significantly linked to the clear cell ovarian carcinomas subtype. Few prognostic or predictive molecular markers for ovary cancer exist yet such markers could be vital for the early diagnosis and management of the disease. The authors propose that in the future serum kisspeptin levels could give a means to monitor disease activity and kisspeptins may even undergo use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities require further research however. They write: "We anticipate that the strong association of GPR54 and kisspeptin expression with outcome and alter cell write in ovarian carcinoma will stimulate fresh approaches to what is comfort a lethally intractable disease."Posted by: Emily

Forex Groups - Tips on Trading

Related article:
http://medicineworld.org/cancer/lead/11-2007/predicting-the-future-in-ovarian-cancer.html

comments | Add comment | Report as Spam

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma and are specific for the clear cell carcinoma subtype research published this week in the online open find journal. BMC Medicine reveals. The kisspeptins a family of peptide hormones and the receptor GPR54 have previously been linked to anti-metastatic activity in certain human tumours. In this study scientists undergo shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian alter cell carcinoma - the first such markers to be identified. A research aggroup based at the BC Cancer Agency and Vancouver General Hospital. Vancouver. Canada created a create from raw material microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive the rest contradict. The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as in comparison to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Scientists also observed that these molecular markers were significantly linked to the clear cell ovarian carcinomas subtype. Few prognostic or predictive molecular markers for ovary cancer exist yet such markers could be vital for the early diagnosis and management of the disease. The authors propose that in the future serum kisspeptin levels could provide a means to monitor disease activity and kisspeptins may even undergo use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities require further research however. They write: "We evaluate that the strong association of GPR54 and kisspeptin expression with outcome and alter cell type in ovarian carcinoma will stimulate fresh approaches to what is comfort a lethally intractable disease."Posted by: Emily

Forex Groups - Tips on Trading

Related article:
http://medicineworld.org/cancer/lead/11-2007/predicting-the-future-in-ovarian-cancer.html

comments | Add comment | Report as Spam

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma and are specific for the clear cell carcinoma subtype research published this week in the online open access journal. BMC Medicine reveals. The kisspeptins a family of peptide hormones and the receptor GPR54 have previously been linked to anti-metastatic activity in certain human tumours. In this study scientists undergo shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian clear cell carcinoma - the first such markers to be identified. A research team based at the BC Cancer Agency and Vancouver General Hospital. Vancouver. Canada created a tissue microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive the be negative. The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as in comparison to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Scientists also observed that these molecular markers were significantly linked to the clear cell ovarian carcinomas subtype. Few prognostic or predictive molecular markers for ovary cancer exist yet such markers could be vital for the early diagnosis and management of the disease. The authors propose that in the future serum kisspeptin levels could provide a means to monitor disease activity and kisspeptins may even have use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities require further investigate however. They write: "We evaluate that the strong association of GPR54 and kisspeptin expression with outcome and clear cell write in ovarian carcinoma will stimulate fresh approaches to what is still a lethally intractable disease."Posted by: Emily

Forex Groups - Tips on Trading

Related article:
http://medicineworld.org/cancer/lead/11-2007/predicting-the-future-in-ovarian-cancer.html

comments | Add comment | Report as Spam

's Cancer evaluate on Market Soon 11/16/2007 Diagnostics developer Healthlinx Ltd hopes to undergo a multi-marker blood test for ovarian cancer on the merchandise in the second accommodate of schedule 2008 after successfully completing a Phase II bio-marker trial on its OvPlex test. A multi-marker evaluate measures five substances in the blood thereby increasing the likelihood of correctly diagnosing the presence of ovarian cancer and reducing the rate of misdiagnosis. A bio-marker is a specific biochemi | | © 2007 DeviceSpace an affiliate Visit other onTargetjobs companies | | | | | | eLearners Online Degrees: | | |

Forex Groups - Tips on Trading

Related article:
http://www.devicespace.com/news_story.aspx?StoryID=77777&full=1

comments | Add comment | Report as Spam

's Cancer Test on merchandise Soon 11/16/2007 Diagnostics developer Healthlinx Ltd hopes to have a multi-marker daub test for ovarian cancer on the merchandise in the back up quarter of calendar 2008 after successfully completing a arrange II bio-marker trial on its OvPlex test. A multi-marker evaluate measures five substances in the blood thereby increasing the likelihood of correctly diagnosing the presence of ovarian cancer and reducing the rate of misdiagnosis. A bio-marker is a specific biochemi | | © 2007 DeviceSpace an affiliate Visit other onTargetjobs companies | | | | | | eLearners Online Degrees: | | |

Forex Groups - Tips on Trading

Related article:
http://www.devicespace.com/news_story.aspx?StoryID=77777&full=1

comments | Add comment | Report as Spam

's Cancer Test on merchandise Soon 11/16/2007 Diagnostics developer Healthlinx Ltd hopes to undergo a multi-marker blood test for ovarian cancer on the merchandise in the second quarter of calendar 2008 after successfully completing a arrange II bio-marker trial on its OvPlex evaluate. A multi-marker test measures five substances in the daub thereby increasing the likelihood of correctly diagnosing the presence of ovarian cancer and reducing the rate of misdiagnosis. A bio-marker is a specific biochemi | | © 2007 DeviceSpace an company Visit other onTargetjobs companies | | | | | | eLearners Online Degrees: | | |

Forex Groups - Tips on Trading

Related article:
http://www.devicespace.com/news_story.aspx?StoryID=77777&full=1

comments | Add comment | Report as Spam